The primary objective of the study is to collect epidemiological data on EGFR mutation status \[M+(mutation positive), M-(mutation negative)\] in a population of predominantly Caucasian ethnicity, and to correlate EGFR mutation status with clinico-pathological characteristics (e.g. smoking status, sex, histology, etc). In particular, the study will aim to determine the frequency of EGFR M+ lung cancers in patients with clinico-pathological characteristics that are not commonly associated with EGFR mutation positivity (i.e., smokers, men, and non-adenocarcinoma).
Study Type
OBSERVATIONAL
Enrollment
589
Research Site
Athens, Athens, Greece
Research Site
Crete, Crete, Greece
Research Site
Ioannina, Ioannina, Greece
Research Site
Kavala, Kavala, Greece
Research Site
Larissa, Larisa, Greece
Research Site
Pátrai, Patra, Greece
Research Site
Ptolemaida, Ptolemaida, Greece
Research Site
Thessaloniki, Thessaloniki, Greece
Research Site
Volos, Volos, Greece
Epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity
Time frame: Up to 2,5 years
Clinico-pathological characteristics according to mutation status
Time frame: Up to 2,5 years
Pharmacoeconomic data (resource use) associated with the diagnosis and treatment of EGFR M+ patients
Time frame: Up to 3,5 years
Real-life data on 1st-line treatment decisions in EGFR M+ and M-/Mx(mutation status not evaluable) patients
Time frame: Up to 2,5 years
Clinical outcome data under real life clinical practice in all EGFR M+ patients up to disease progression (PFS, OS, DCR)
Time frame: Up to 3,5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.